ALEXANDRA PHILIPSEN
Germany
Since 2018: Director and W3 Professor of the Dept. of Psychiatry and Psychotherapy, University of Bonn. Since 2021: Deputy Medical Director of the University Hospital Bonn. 2014-2017: Director and W3 Professor of the Dept. of Psychiatry and Psychotherapy, Karl Jaspers Klinik, European Medical School, Oldenburg-Groningen. 2009-2014: Executive Senior Physician, Department of Psychiatry and Psychotherapy, University of Freiburg. 2009: Habilitation "on the etiology, symptomatology and therapy of attention-deficit/hyperactivity disorder in adults". 1999: Dr. med. "Botulinum toxin A as a new therapy option in neuropaediatrics, University of Freiburg. Supervisor for cognitive behavior therapy, dialectical behavior therapy. Scientific focus: translational therapy research on attention and emotion regulation, development and evaluation of pharmacological and non-pharmacological treatments for ADHD in adults. Precision Medicine.
Clinical focus: diagnosis and treatment of the entire spectrum of mental disorders, especially affective disorders such as depression, stress-associated disorders, ADHD in adulthood and personality disorders, crisis intervention and suicidality. Scientific advisor of ADHS-Deutschland (https://adhs-deutschland.de/Home.aspx), member of the steering board of the German ADHD Network (www.zentrales-adhs-netz.de). Member of the Adivsory Board on Psychotherapy, Germany. Since 2023 President elect, Chairs of Psychiatry and Psychotherapy, Germany.
Germany
Since 2018: Director and W3 Professor of the Dept. of Psychiatry and Psychotherapy, University of Bonn. Since 2021: Deputy Medical Director of the University Hospital Bonn. 2014-2017: Director and W3 Professor of the Dept. of Psychiatry and Psychotherapy, Karl Jaspers Klinik, European Medical School, Oldenburg-Groningen. 2009-2014: Executive Senior Physician, Department of Psychiatry and Psychotherapy, University of Freiburg. 2009: Habilitation "on the etiology, symptomatology and therapy of attention-deficit/hyperactivity disorder in adults". 1999: Dr. med. "Botulinum toxin A as a new therapy option in neuropaediatrics, University of Freiburg. Supervisor for cognitive behavior therapy, dialectical behavior therapy. Scientific focus: translational therapy research on attention and emotion regulation, development and evaluation of pharmacological and non-pharmacological treatments for ADHD in adults. Precision Medicine.
Clinical focus: diagnosis and treatment of the entire spectrum of mental disorders, especially affective disorders such as depression, stress-associated disorders, ADHD in adulthood and personality disorders, crisis intervention and suicidality. Scientific advisor of ADHS-Deutschland (https://adhs-deutschland.de/Home.aspx), member of the steering board of the German ADHD Network (www.zentrales-adhs-netz.de). Member of the Adivsory Board on Psychotherapy, Germany. Since 2023 President elect, Chairs of Psychiatry and Psychotherapy, Germany.